1. In Vivo
  2. >>Business Strategy

Liquid Biopsy On Course To Transform Cancer Management

 
• By Peter Charlish

Liquid biopsies look set to revolutionize the management of cancer patients.  A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.

IV1705_LiquidBiopsy_1200

Although the survival rates for many types of cancer have improved significantly in recent years, cancer was still responsible for 8.8 million deaths worldwide in 2015, or nearly one in six of all deaths, making it the second biggest cause of death globally after coronary heart disease.

In the past few years, scientific advances such as tumor genome sequencing have helped to identify the genetic basis of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By David Wild

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Patient-Centric Strategy Drives Memo Therapeutics Forward

 
• By Anabel Costa-Ferreira

Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.

Small Biotech, Big Breakthrough: Abivax Enters A New Era

 
• By Lucie Ellis-Taitt

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.

More from In Vivo

Execs On The Move: October 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By David Wild

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.